18F-FLUC-CEST PET/MR in Patients With Brain Mets

Radiation Therapy Clinical Trial

Official title: Use of Amide-CEST MRI and 18F-Fluciclovine PET for Discerning Tumor From Treatment Change in Patients With Brain Metastases Undergoing Immunotherapy

Status Recruiting

Clinical Trial Summary

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining. Participants will undergo a single PET/MRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.

Clinical Trial Description

The purpose of this research is to utilize new imaging methods to aid in assessing whether imaging shows presence of tumor. Developing imaging technologies is critical for more accurately identifying location and amount of tumor, which will then lead to improvements in future cancer therapy. This study aims to evaluate imaging methods known as PET and MRI to improve detection of cancerous tissue better than the types of imaging that are currently available. These methods are conducted on the same machine as conventional MRI that uses a powerful magnet, radio waves, and a computer to create detailed images. Both the PET and MRI methods look at the number of proteins a tumor has. The more proteins, the more likely there is tumor relative to normal brain tissue. ;

Related Conditions & MeSH terms

• Brain Metastasis
• Brain Neoplasms
• Immunotherapy, Active
• Neoplasm Metastasis
• Radiation Therapy

• NCT number: NCT06159335
• Study type: Interventional
• Source: University of Wisconsin, Madison
• Contact: Suzanne Hanson
• Phone: 608-263-9179
• Email: radstudy@uwhealth.org
• Status: Recruiting
• Phase: Phase 3
• Start date: January 10, 2024
• Completion date: December 2024